Carcinoma, Transitional Cell
2 competing products in clinical development for Carcinoma, Transitional Cell.
Pipeline by Phase
Phase 1/21
Phase 21
All Products (2)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| enfortumab vedotin (EV) + pembrolizumab + cisplatin + carboplatin + gemcitabine | Astellas Pharma | Phase 1/2 | Active | 36 |
| Enfortumab vedotin | Astellas Pharma | Phase 2 | Completed | 35 |